FDA Brief

Warning letters Food

FDA warning letter to

Flora Inc

High riskIssued Jun 7, 2021Posted Jun 29, 2021Division of Human and Animal Food Operations West VI

Flora Inc marketed supplements and foods with website claims that made them unapproved new drugs, including COVID-19 claims for Elderberry+.

What happened

FDA reviewed Flora Inc's website at florahealth.com/us from March through May 2021 and its Pinterest page, which directed consumers to the website. FDA found the site took orders for ten named products and contained claims that they cure, mitigate, treat, or prevent diseases; FDA specifically said Elderberry+ was intended to mitigate, prevent, treat, diagnose, or cure COVID-19.

What FDA found

  1. Website claims showed the products were intended to cure, mitigate, treat, or prevent disease, making them drugs under the Act.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are 'new drugs'—products not generally recognized as safe and effective and not FDA-approved—and were sold without approval.

    section 201(p) [21 U.S.C. § 321(p)]; sections 301(d) and 505(a) [21 U.S.C. § 331(d), § 355(a)]
  3. Sleep•Essence, Cardio•Essence, Elderberry+, Elderberry Crystals, Flor•Essence, Hydro-Therm Pumpkin Oil, and Pumpkin Oil lacked adequate directions for use because their intended diseases are not suitable for self-diagnosis or treatment.

    section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Introducing these misbranded drugs into interstate commerce violates the Act.

    section 301(a) [21 U.S.C. § 331(a)]
  5. Elderberry+ was promoted with claims that implied it could prevent or treat COVID-19 without FDA approval or authorization.

    section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]

What FDA wants

FDA asks Flora Inc to take immediate action to stop selling unapproved or unauthorized products for COVID-19 and, within 15 working days of receipt, to notify FDA in writing of specific steps taken, documentation, and how it will prevent recurrence. If it cannot finish within that time, it must state why and when it will; if it disagrees, it must give reasoning and supporting information.

Who should pay attention

  • dietary supplement and herbal product brands
  • e-commerce sellers making health claims
  • companies marketing COVID-19-related products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk